帕金森疾病研究迈入新时代
我们相信，通过分享我们的知识和行业见解，可以扩大我们的影响力，并让我们离减轻帕金森疾病及其他神经系统疾病患者的痛苦更近一步。
我们的首席科学家团队经常聚集，评估、分析并深入探讨最新的科研动态与进展。依托我们在神经科学与临床前研究方面的全球领先的长期经验来推动解决围绕新疗法的科学和商业开发过程中关键问题、挑战与趋势的的讨论和交流。这就是我们的日常开展科研的方式。
发现系列
#3 – LRRK2
Read the latest in our ongoing series on the latest scientific research behind emerging targets in Parkinson’s Disease
Leucine-rich repeat kinase 2 (LRRK2)-targeted therapies for the treatment of Parkinson’s disease
白皮书
Redefining Parkinson’s Disease
A primer on the emerging biological understanding of Parkinson’s and its possible impact on the development of novel therapeutics and disease modelling.
与我们的专家进行交流
赋能您的研发项目
获取来自 Atuka 的最新科学进展
订阅我们的季刊，了解帕金森疾病研究领域的最新进展。
新闻与行业见解
-
Aligning in vivo models of Parkinson’s disease with biological classifications
-
The importance of data management in ensuring the integrity of biomedical research
-
Towards a cure, through collaboration and clarity: Perspectives from the 2025 MJFF Therapeutics Conference
-
A quality system that boosts both research integrity and innovation
-
Better data, better reproducibility: the importance of quality systems
发现系列
#2 – BDNF/TrkB
Read the latest in our ongoing series on the latest scientific research behind emerging targets in Parkinson’s Disease
The Potential of BDNF/TrkB Pathway Modulation in Parkinson’s Disease
白皮书
从临床前角度看基因疗法的未来
基因疗法的潜力终于得到了发挥，这些疗法有望为多种疾病带来改变人生的治疗方案。
Atuka 首席创新官 Patrick A. Howson 博士深入探讨了基因疗法的过去、现在与未来。